Home SJS Info Drugs Causing SJS SJS Complications SJS & Children Side Effects SJS Attorney
(Reuters) - The head of the U.S. House Oversight and Government Reform Committee expanded his investigation of Johnson & Johnson on Tuesday, saying another 2008 recall casts doubt on the drugmaker's pledge of protecting consumers.
Chairman Edolphus Towns, in a letter to the drugmaker, asked the company for all records related to the 2008 recall of some adult versions of its Motrin pain reliever, including the identities of employees involved, as well as outside contractors and subcontractors who worked for J&J.
The letter follows a May 27 hearing on the latest J&J recall of more than 40 liquid children's medications, including Children's Tylenol.
At the hearing, Towns questioned the 2008 incident, calling it a "phantom recall" in which J&J-hired contractors were instructed to buy the Motrin products from various retailers, "'act' like a regular customer" and not mention any recall.
When the U.S. Food and Drug Administration later found out about the purchases, J&J initiated a formal recall, Towns said, citing internal company documents the committee reviewed as part of its probe.
Colleen Goggins, worldwide chairman of J&J's consumer group, told lawmakers at the hearing that J&J had sought to obtain certain Motrin products sold mostly at gasoline stations to determine whether a recall was needed.
Stevens Johnson Syndrome Medical Literature
What is Stevens Johnson Syndrome?
The government said today it may take criminal action against the giant pharmaceutical company Johnson & Johnson over sloppy quality control that led to last month’s massive recall of Dilantin Cerebellar Atrophy Risks infant’s and children’s liquid medicines.
The recall of products made by J&J’s McNeil Consumer Healthcare subsidiary took 136 million bottles of medicines off the shelves, including 40 varieties of popular brands such as Children’s Tylenol, Infant’s Tylenol, Children’s Motrin, Children’s Zyrtec and Children’s Benadryl. The recall involved 70 percent of the market for those products.
Both the Food and Drug Administration and J&J say there is no evidence yet that any child has been harmed from using one of the recalled products, but the investigation continues. The FDA says brands currently being sold in drugstores are safe to use.
Nevertheless, the FDA said if parents are concerned, they should buy generic medicine for their kids.
The products were recalled April 30, 2010, after the FDA found problems with their quality, purity and potency. Manufacturing deficiencies were found at McNeil’s plant in Fort Washington, Pennsylvania, which has since closed and remains shut down. It was the third major recall of McNeill products in eight months due to quality problems, including some drugs whose foul odor reportedly made customers vomit.
Joshua Sharfstein, principal deputy commissioner at the FDA, told the House Committee on Oversight and Government Reform, the agency was “considering additional enforcement actions against the company which may include seizure, injunction and criminal penalties.”
Deborah Autor, the head of FDA’s Office of Compliance, said, “The FDA’s center for drugs has referred this to FDA’s criminal investigative unit, and then they have to judge where to go from there.” FDA officials said they did not know how long such a review would take.
Sharfstein said, “Although the public health risks from these quality problems is low, these problems should never have occurred. And the manufacturing failures at the facility that caused them were unacceptable.”
The head of Johnson & Johnson’s Consumer Group, Colleen Goggins, agreed. “The quality and process issues that we found at McNeil, those which led to the recall and others, are unacceptable,” she said.”On behalf of McNeil and Johnson & Johnson, I apologize to the mothers, fathers, and caregivers for the concern and inconvenience caused by the recall.”
But Goggins defended the company’s handling of the recall and denied it ever knowingly used any contaminated products. She said McNeil has “made significant organizational changes,” hiring new officials to oversee quality and plant operations.
Committee chairman Rep. Edolphus Towns, D-New York, said, “There is nothing this committee will investigate that is more serious than the health of our children. We will use all of our authority to find out what went wrong and do everything that we can to ensure that it does not happen again.”
Rep. Towns wanted an assurance no one could give him. “Can you say with complete certainty that no children who took the medicines that were recalled last month were harmed by them?” he asked.
Possibly related posts: (automatically generated)